News

Syngenta is on a shopping spree
Enlarge image

BusinessSwitzerlandBelgiumGermany

Syngenta is on a shopping spree

24.09.2012 - Syngenta is set to buy two biotech companies: The Swiss firm is willing to pay up about €500m for seed maker Devgen NV and Pasteuria Biosciences.

Syngenta announced an offer to acquire all outstanding shares of Devgen NV at a price of €16 in cash per share, valuing the Belgian hybrid rice seed producer at €403m in total. The offer price represents a premium of 70% to Devgen's closing price on NYSE Euronext Brussels on 20 September 2012, the day before the tender offer was made public. 

The Belgian group posted sales of €25.5m and an operational loss of €6.3m in 2011. Created in 1997, the company employs 250 people and among its products is a hybrid rice developed for India and South-east Asia. The asset will have a “very significant impact” on Syngenta’s $500 million rice business, Chief Operating Officer Davor Pisk said in an interview today. "We are also buying their competence in RNAi technology which are relevant for us across a broad range of crops“, added Syngenta spokeswoman Jennifer Gough.

This is Syngenta's second deal announced within a week. Only days before, Swiss company revealed its plans to acquire Pasteuria Biosciences for €87m. Since 2011, Syngenta and the US company have had an exclusive global technology partnership to develop and commercialise biological products to control plant-parasitic nematodes, using the naturally occurring soil bacteria Pasteuria spp.

With its acquisition strategy, Syngenta reacts to the increasingly fierce competition with agribusiness companies Bayer and BASF both of Germany. BASF recently announced the intention to buy Becker Underwood for €785m, while Bayer decided months ago to purchase US-based AgraQuest for €340m plus milestone payments.

© eurobiotechnews.eu/bk

BusinessUKIreland

21.07.2014 Abbvie’s tenacious pursuit of British rival Shire is finally paying off: The two companies have unveiled their transatlantic merger worth £32bn (€40bn).

ResearchEUSwitzerland

17.07.2014 A trans-border, cross-disciplinary project that aims to model the human brain in a computer has drawn heavy criticism from scientists pledging to boycott the project.

MergerUK

16.07.2014 After rejecting three merger propositions from US competitor Abbvie, Shire has now given up resistance to the deal and is recommending a new and improved offer worth £31.3bn.

AcquisitionUKDenmarkSpainGermanyFrance

15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Stock marketNetherlandsUKBelgium

10.07.2014 Not one but two biopharma companies are seeking entry into the stock market: After Abzena raised €25m in an IPO earlier this week, Argen-x has followed suit and sold shares worth €40m.

M and AUKIreland

08.07.2014 Abbvie is determined to bring home British rare disease specialist Shire in a merger worth £30.1bn (€37.9bn). So far, Shire has rejected all offers from the US company.

M and ASwitzerland

04.07.2014 Genentech, a member of Swiss Roche Group, is set to acquire US-biotech Seragon Pharmaceuticals Inc. With the move, Genentech will obtain the rights to investigational breast cancer treatments.

MandAFranceGermany

03.07.2014 Nicox S.A. is stretching beyond the European market: The French eye health specialist is set to acquire Aciex Therapeutics Inc., a US-based pharma company with several ophthalmic therapeutics nearing market maturity.

FinanceBelgium

01.07.2014 Belgian antibody specialist Ablynx has raised €41.7m through a private placement of new shares and plans on boosting their range of nanobodies in development.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MAGFORCE (D)5.90 EUR9.26%
  • ABCAM (UK)387.00 GBP7.72%
  • NANOBIOTIX (F)17.40 EUR7.27%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.40 EUR-8.33%

TOP

  • WILEX (D)3.12 EUR310.5%
  • SANTHERA (CH)69.30 CHF132.6%
  • ADDEX (CH)4.07 CHF89.3%

FLOP

  • MERCK KGAA (D)63.71 EUR-50.0%
  • THROMBOGENICS (B)8.87 EUR-38.3%
  • HYBRIGENICS (F)1.72 EUR-34.1%

TOP

  • SANTHERA (CH)69.30 CHF3365.0%
  • GW PHARMACEUTICALS (UK)438.00 GBP812.5%
  • PAION (D)2.80 EUR311.8%

FLOP

  • CYTOS (CH)0.25 CHF-92.7%
  • EVOCUTIS (UK)0.21 GBP-92.1%
  • THROMBOGENICS (B)8.87 EUR-71.1%

No liability assumed, Date: 22.07.2014